A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

NCT05735327 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: No intervention

Sponsor

Takeda